Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model

Prior research has shown that concerns regarding donor blood safety have driven the increased adoption of intraoperative salvage technology. That uncertainty drove clinicians to integrate these devices into standard surgical protocols for aortic repair. No prior work had resolved whether this widespread application provides sufficient economic value compared to traditional transfusion methods. This gap motivated the development of a formal economic evaluation framework. It was already known that transfusion-related risks include various viral infections and immune reactions. However, the specific financial impact of these risks within elective infrarenal aortic reconstruction remained poorly defined. This study addresses the necessity of balancing clinical safety with fiscal responsibility in modern operating rooms. The current investigation provides a structured assessment of whether these devices meet standard benchmarks for healthcare spending efficiency.

The aim of this study was to determine if the routine use of an intraoperative autologous transfusion device is cost-effective during elective infrarenal aortic reconstructions. Researchers sought to evaluate whether the financial investment in this technology aligns with standard economic benchmarks for healthcare interventions. They specifically examined the $50,000 per quality-adjusted life year threshold to assess value. The study addressed the clinical and economic trade-offs between using salvaged blood and traditional donor blood products. By modeling various transfusion-related complications, the authors intended to clarify the role of these devices in modern vascular surgery. This investigation was motivated by the widespread adoption of salvage technology despite limited evidence regarding its fiscal impact. The researchers aimed to provide a clear decision-making framework for surgeons and hospital administrators. Ultimately, the work seeks to optimize resource allocation by identifying which patient groups derive the most benefit from this technology.

The review approach involved constructing a decision analysis tree to simulate all complications linked to red blood cell replacement. Investigators gathered transfusion requirements from a retrospective analysis of elective surgeries performed between 1991 and 1995. This cohort included sixty-three aneurysm cases and seventy-five occlusive disease cases. Researchers obtained risk profiles for allogenic transfusion-related infections from established medical literature and institutional audits. The team defined a single unit of salvaged return as equivalent to one unit of donor packed red blood cells. They calculated costs in dollars and quality-adjusted life years to determine economic efficiency. Sensitivity analyses tested the impact of varying infection rates on the overall model outcomes. This structured methodology allowed for a comprehensive comparison between routine device application and standard donor blood transfusion practices.

Key findings from the literature indicate that routine device application is not cost-effective for elective infrarenal aortic reconstruction. For abdominal aortic aneurysm repairs, the procedure cost $263.75 while yielding only 0.00218 quality-adjusted life years. This resulted in an expenditure of $120,794 for each quality-adjusted life year gained. Aortoiliac occlusive disease repairs proved even less efficient, costing $356.68 for a benefit of 0.00062 quality-adjusted life years. This equates to a rate of $578,275 per quality-adjusted life year, far exceeding the $50,000 threshold. Sensitivity analyses revealed that the device would only reach cost-effectiveness for aneurysms if hepatitis C incidence increased tenfold. Furthermore, the model demonstrated that salvage volumes must exceed 5 units for aneurysms and 6 units for occlusive disease to justify the cost. These results suggest that universal use of the technology provides minimal economic or clinical advantage.

The authors conclude that routine implementation of salvage technology during elective infrarenal aortic reconstruction fails to meet standard cost-effectiveness thresholds. This synthesis and implications review suggests that universal application of these devices is not justified by the observed clinical benefits. The researchers propose that surgical teams should reserve these tools for patients expected to require high volumes of salvaged blood. Alternatively, the device may serve as a standby reservoir for unexpected, significant hemorrhage during the procedure. The analysis indicates that the economic viability of these systems depends heavily on the volume of blood recovered. Future practice should prioritize selective use based on anticipated intraoperative blood loss rather than universal adoption. These findings highlight the importance of balancing technological integration with rigorous economic scrutiny in vascular surgery. The study emphasizes that resource allocation must be guided by clear evidence of patient benefit and financial sustainability.